###### Implications

-   For many patients with chronic organ failure, transplantation is the only therapeutic option, but the number of donated human organs and tissues falls far short of the need.

-   Porcine cells, tissues, and organs likely will be an alternative transplant source, since pigs can be genetically engineered to overcome rejection mechanisms and physiological incompatibilities, and to reduce the risk of transmitting zoonotic pathogens.

-   Significant progress has been made in many areas of xenotransplantation, including pancreatic islets, neuronal cells, and corneas, but also vascularized organs, especially kidneys and hearts.

-   In view of recent preclinical breakthroughs, such as consistent long-term survival of baboons after orthotopic transplantation of a genetically multimodified porcine heart, xenotransplantation can be considered as a realistic future therapeutic option.

Introduction {#s1}
============

The number of donated human organs and tissues for patients with terminal organ failure falls far short of the need. According to the United Network for Organ Sharing ([www.unos.org](http://www.unos.org)), more than 113,000 candidates for transplant are currently on the U.S. national waiting list, but only 36,527 organ transplants could be performed in 2018. Alternative sources, such as organs and tissues from animals, are therefore urgently needed. For a number or reasons, including size, anatomical, and physiological similarities with humans, the pig is the preferred donor species (reviewed in [@CIT0007]). Importantly, pigs can be optimized by genetic engineering as a source of cells, tissues, and organs for xenotransplantation. Recent advances in gen(om)e editing are speeding up progress in this field. Numerous genetically (multi-)modified pig lines have been generated to prevent immune rejection of xenotransplants, to overcome physiological incompatibilities, and to reduce the risk of transmitting zoonotic pathogens ([Table 1](#T1){ref-type="table"}; reviewed in [@CIT0023]).

###### 

Selection of genetic modifications of donor pigs for xenotransplantation

  Aim/Genetic modification (GM)                                                       Reference
  ----------------------------------------------------------------------------------- --------------------------------------
  Deletion of sugar moieties of pig cells with pre-formed recipients' antibodies      
   α-1,3-galactosyltransferase knockout (GGTA1-KO)                                    ([@CIT0044])
   Cytidine monophosphate-N-acetylneuraminic acid hydroxylase knockout (CMAH-KO)      ([@CIT0030]; [@CIT0035])
   β-1,4-N-acetyl-galactosaminyl transferase 2 knockout (B4GALNT2-KO)                 ([@CIT0014])
  Complement regulation by human complement-regulatory gene expression                
   Human membrane cofactor protein transgenic (hCD46-tg)                              ([@CIT0011])
   Human decay-accelerating factor transgenic (hCD55-tg)                              ([@CIT0009])
   Human protectin or membrane inhibitor of reactive lysis transgenic (hCD59-tg)      ([@CIT0017])
   Human complement-regulatory protein C1 inhibitor transgenic (hC1-INH-tg)           ([@CIT0029])
  Coagulation regulation by human coagulation-regulatory gene expression              
   Human thrombomodulin transgenic (hTBM-tg)                                          ([@CIT0053])
   Human endothelial protein C receptor transgenic (hEPCR-tg)                         ([@CIT0021])
   Human tissue factor pathway inhibitor transgenic (hTFPI-tg)                        ([@CIT0034])
   Human ectonucleoside triphosphate diphosphohydrolase-1 transgenic (hCD39-tg)       ([@CIT0051])
   Human ecto-5′-nucleotidase transgenic (hCD73-tg)                                   ([@CIT0033])
  Prevention of cell-mediated rejection - T cells                                     
   Human LEA29Y transgenic (LEA29Y-tg)                                                ([@CIT0028]; [@CIT0002])
   Human CTLA4-Ig transgenic (hCTLA4-Ig-tg)                                           ([@CIT0036])
   Porcine CTLA4-Ig transgenic (pCTLA4-Ig-tg)                                         ([@CIT0043])
   SLA class I knockout                                                               ([@CIT0046])
   Human dominant-negative mutant class II transactivator transgenic (CIITA-DN-tg)    ([@CIT0018])
   Human TNF-related apoptosis-inducing ligand transgenic (hTRAIL-tg)                 ([@CIT0026])
   Human-programmed cell death 1 ligand 1 transgenic (PD-L1-tg)                       ([@CIT0005])
  Prevention of cell-mediated rejection - natural killer cells and macrophages        
   HLA-E/human b2-microglobulin transgenic (HLA-E/b2M-tg)                             ([@CIT0050])
   Human CD47 transgenic (hCD47-tg)                                                   ([@CIT0047])
  Expression of anti-inflammatory proteins or knockout of pro-inflammatory proteins   
   Human tumor necrosis factor α--induced protein 3 (TNFAIP3) transgenic (A20-tg)     ([@CIT0041])
   Human heme oxygenase 1 transgenic (hHO-1-tg)                                       ([@CIT0042])
   Soluble human TNFRI-Fc transgenic (shTNFRI-Fc-tg)                                  ([@CIT0054])
  Reduction/elimination of the risk of PERV transmission                              
   Knockdown of PERV expression                                                       ([@CIT0037]; [@CIT0012]; [@CIT0045])
   Genome-wide inactivation of PERV pol gene                                          ([@CIT0040])
  Genetically multimodified pigs                                                      
   GGTA1-KO/hCD46-tg/hCD39-tg                                                         ([@CIT0004])
   GGTA1-KO/hCD46-tg/hTFPI-tg/pCTLA4-Ig-tg                                            ([@CIT0004])
   GGTA1-KO/hCD46-tg/hTFPI-tg/pCTL4-Ig-tg/hCD39-tg                                    ([@CIT0004])
   GGTA1-KO/hCD55-tg/hCD59-tg/human fucosyltransferase (HT)-tg                        ([@CIT0032])
   GGTA1-KO/hCD55-tg/hCD59-tg                                                         ([@CIT0020])
   GGTA1-KO/hCD55-tg/hCD39-tg/TFPI-tg/hC1-INH-tg/hTNFAIP3-tg                          ([@CIT0029])
   GGTA1-KO/CMAH-KO/hCD46-tg/hCD55-tg/hCD59-tg/hA20-tg/hHO1-tg                        ([@CIT0015])

Genetic modifications to overcome hyperacute and acute vascular rejection of pig-to-primate xenotransplants {#s2}
-----------------------------------------------------------------------------------------------------------

Hyperacute rejection of vascularized pig-to-primate xenotransplants is triggered by binding of preformed antibodies of the recipient to specific antigens on the xenogeneic tissue and subsequent activation of the complement system. The major xeno-antigen is galactose-α1,3-galactose (αGal) synthesized by α-1,3-galactosyltransferase (GGTA1). Humans and Old World monkeys lack GGTA1 and αGal epitopes, but are exposed to bacterial αGal epitopes eliciting a persistent anti-αGal antibody response in early life. Other prominent xeno-antigens are N-acetylneuraminic acid (Neu5Gc) synthesized by cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) and an Sd(a)-like glycan made by porcine β-1,4-N-acetyl-galactosaminyl transferase 2 (B4GALNT2) (reviewed in [@CIT0006]).

An important step toward long-term survival of vascularized porcine xenotransplants in nonhuman primates was the generation of pigs lacking functional *GGTA1* alleles ([@CIT0044]). Subsequently, multiple *GGTA1* knockout pig lines were generated, initially by gene targeting (reviewed in [@CIT0027]) and later by gene editing (e.g., [@CIT0019]). In addition, pigs with knockout mutations of *CMAH*, *B4GALNT2* or combinations of these modifications were generated ([@CIT0014]). The authors showed that cells from GGTA1/CMAH/B4GALNT2--deficient pigs exhibited reduced human IgM and IgG binding compared with cells lacking only GGTA1 and CMAH.

A complementary strategy is the generation of transgenic pigs that express human complement-regulatory proteins, such as CD46 (membrane cofactor protein, MCP), CD55 (complement decay-accelerating factor, DAF), or CD59 (membrane inhibitor of reactive lysis, MIRL), singly or in combination. These complement-regulatory proteins attenuate complement activation and significantly prolong survival of pig-to-nonhuman primate xenotransplants (reviewed in [@CIT0007]).

By combination of *GGTA1* knock-out with the expression of one or more human complement-regulatory proteins, the problem of hyperacute rejection of porcine xenotransplants in nonhuman primates has been solved. For clinical trials, additional knock-outs of *CMAH* and *B4GALNT2* may be required (reviewed in [@CIT0023]).

Besides preformed antibody binding to carbohydrate antigens, xenotransplantation of porcine cells, tissues, or organs elicits a humoral immune response (reviewed in [@CIT0048]). The risk is likely increased in presensitized patients with antibodies against major histocompatibility complex (MHC) class I molecules/human leukocyte antigens, since these antibodies may cross-react with conserved epitopes of swine MHC subclasses/swine leukocyte antigens ([@CIT0039]). To overcome this problem, pigs lacking MHC class I have been generated. These pigs showed reduced levels of CD4^−^ CD8^+^ T cells in the peripheral blood, but appeared healthy and developed normally ([@CIT0046]).

Genetic modifications to overcome cellular rejection of pig-to-primate xenotransplants {#s3}
--------------------------------------------------------------------------------------

Cellular rejection of pig-to-primate xenotransplants involves both innate and adaptive components of the cellular immune system. Immune cell infiltration of tissue and solid organ xenotransplants starts with neutrophils, followed by macrophages and T cells (reviewed in [@CIT0048]). In addition, natural killer cells may induce endothelial cell activation in the xenotransplant and lyse porcine cells directly and via antibody-dependent cytotoxicity (reviewed in [@CIT0050]).

Cellular xenotransplants such as porcine islets in nonhuman primates are mainly rejected by CD4^+^ T cells. Their activation can be induced by direct binding of primate T-cell receptors to swine leukocyte antigen class 1 and class 2 molecules of porcine cells, or indirectly by antigen-presenting cells of the recipient expressing MHCs with processed xeno-antigens (reviewed in [@CIT0048]). In addition, co-stimulatory signals, which may induce and amplify an effective immune response, or exhibit an inhibitory function, are involved in the regulation of T-cell function. The most prominent T-cell co-stimulatory signaling complexes are CD40 (on APCs)-CD154 (on T cells) and CD80/CD86 (on antigen-presenting cells)-CD28 (on T cells). The CD80/CD86-CD28 co-stimulation pathway can be blocked by systemic treatment with CTLA4-Ig (abatacept) or its affinity-optimized version LEA29Y (belatacept) (reviewed in [@CIT0003]). These molecules can also be expressed in genetically modified donor pigs, opening the prospect of inhibiting T-cell activation locally at the graft site, thus avoiding systemic immunosuppression of the recipient and the consequent risk of infection. Protective effects of human CTLA4-Ig expression on porcine cells and tissues were shown in xenogeneic neuronal cell ([@CIT0001]) and skin transplantation experiments ([@CIT0049]).

LEA29Y expressing transgenic porcine neonatal islet-like cell clusters transplanted into immunodeficient diabetic mice normalized blood glucose levels and, in contrast to wild-type neonatal islet-like cell clusters, were not rejected after the recipient mice were reconstituted with human immune cells ([Figure 1](#F1){ref-type="fig"}) ([@CIT0028]). A subsequent study using diabetic mice with a long-term "humanized" immune system as recipients showed that LEA29Y expressing porcine neonatal islet-like cell clusters survived for several months and normalized the recipients' blood glucose levels, whereas wild-type islets did not engraft in this model ([@CIT0052]). Neonatal islet-like cell clusters have a number of advantages over adult porcine islets, most importantly their straightforward isolation, their proliferation capacity, their superior revascularization after transplantation, and the fact that donor animals do not need to be maintained for a long period under expensive designated pathogen-free conditions (reviewed in [@CIT0024]). However, neonatal islet-like cell clusters are immature and not fully functional after isolation. To visualize the maturation and proliferation of neonatal islet-like cell clusters, we generated transgenic pigs expressing enhanced green fluorescent protein (eGFP) under the control of the porcine insulin gene (*INS*) promoter. The reporter gene is expressed specifically in beta cells and the level of expression increases upon beta-cell maturation ([@CIT0022]). This model is useful to study beta-cell maturation and expansion in vivo, e.g., after transplantation into the anterior eye chamber of mice. Moreover, eGFP-expressing beta cells can be recovered by fluorescence-activated cell sorting and processed for molecular profiling studies, such as single-cell RNA sequencing ([@CIT0024]).

![Protection of xenotransplanted porcine pancreatic islets against T-cell mediated rejection by local expression of LEA29Y. (A) Principle of co-stimulation blockade of T cells. Activation of T cells requires interaction between the T-cell receptor and a peptide-loaded MHC on an antigen-presenting cell (APC). In addition, a second signal such as the interaction between CD28 und CD80/CD86 is required. The interaction of CTLA4 and CD80/CD86 blocks T-cell activation. The latter can also be achieved by the soluble molecule CTLA4-Ig or its affinity-optimized version LEA29Y. (B) Immunohistochemical staining of LEA29Y in pancreas sections from INS-LEA29Y transgenic pigs. (C) Transplantation of neonatal islet-like cell clusters (NICCs) from wild-type (WT) or INS-LEA29Y transgenic pigs (LEA29Y) under the kidney capsule of immune deficient streptozotocin (STZ)-diabetic NSG mice results in an insulin-positive cell mass that is able to normalize their blood glucose level. If the mice are subsequently reconstituted with human peripheral blood mononuclear cells (hPBMCs), the WT islets are rejected while the LEA29Y transgenic islets are protected ([@CIT0028]). (D) Histology of the transplantation site. In recipients of WT NICCs, very few insulin-positive cells were found, but a massive T-cell infiltration (shown by CD45 staining) was evident. In contrast, LEA29Y expressing NICCs survived and formed large clusters of insulin-positive cells. T-cell infiltration was observed in the periphery, but not within the insulin-positive cell clusters.](vfz014f0001){#F1}

To prevent lysis of xenogeneic cells by natural killer cells, transgenic pigs expressing HLA-E/beta2-microglobulin were generated. Their cells were effectively protected against human natural killer-cell mediated cytotoxicity, depending on the level of CD94/NKG2A expression on the natural killer cells ([@CIT0050]). To control macrophage activity, human CD47 has been expressed on porcine cells to activate the "don't eat me signal" receptor SIRPα on (human) monocytes/macrophages and to suppress phagocytic activity (reviewed in [@CIT0007]).

Genetic modifications to overcome dysregulation of coagulation and inflammation {#s4}
-------------------------------------------------------------------------------

Dysregulation of coagulation and disordered hemostasis are frequent complications in preclinical pig-to-nonhuman primate xenotransplantation studies. Inflammation, vascular injury, innate, humoral and cellular immune responses, and, in particular, molecular incompatibilities between porcine and primate regulators of coagulation are discussed as potential causes (reviewed in [@CIT0008]).

Key endothelial anticoagulant/antithrombotic proteins that have been modified/supplemented by genetic engineering of donor pigs include human thrombomodulin (TBM), endothelial protein C receptor, tissue factor pathway inhibitor, and ectonucleoside triphosphate diphosphohydrolase 1 (CD39) (reviewed in [@CIT0008]). Porcine thrombomodulin binds human thrombin, but is a poor co-factor for activation of human protein C. Therefore, we generated transgenic pigs expressing human thrombomodulin under the control of the porcine thrombomodulin gene (*THBD*) promoter ([Figure 2](#F2){ref-type="fig"}) ([@CIT0053]). A *GGTA1* knockout, hCD46/hTBM transgenic pig heart survived for 945 d after heterotopic abdominal transplantation into a baboon with appropriate immunosuppression ([@CIT0038]).

![Expression of human thrombomodulin (hTBM) in genetically (multi-)modified pigs. (A) Expression vector with the porcine *THBD* gene promoter. (B) Immunofluorescence staining of hTBM in transgenic porcine endothelial cells. (C) Expression of hTBM in vascular endothelial cells of myocardium from transgenic pigs. (D) Beads covered with hTBM expressing endothelial cells from genetically (multi-)modified pigs delay clotting of human blood ([@CIT0053]).](vfz014f0002){#F2}

In addition to modifications targeting coagulation disorders in xenotransplantation, transgenic pigs expressing antiapoptotic and antiinflammatory proteins, such as human tumor necrosis factor-alpha-induced protein 3 (A20) ([@CIT0041]) and human heme oxygenase-1 (HO-1) ([@CIT0042]), have been produced.

Genetic modifications to decrease the risk for zoonoses {#s5}
-------------------------------------------------------

Xenotransplantation may be associated with the risk of transmission of porcine microorganisms including bacteria, fungi, and viruses able to adapt in the recipient and to induce a disease (zoonosis or xenosis) (reviewed in [@CIT0016]). Many microorganisms can be eliminated from the donor pigs by selection, treatment with antibiotics, antimycotics or antiviral drugs, by vaccination, by early weaning and colostrum deprivation, by caesarean delivery or embryo transfer, and by maintenance of the donor animals in designated pathogen-free housing facilities (reviewed in [@CIT0023]). An example is the elimination of porcine cytomegalovirus by early weaning of piglets, even if their mothers were infected ([@CIT0013]).

In contrast, porcine endogenous retroviruses (PERVs) cannot be eliminated this way, because they are integrated in the genome of all pigs and can be released from pig tissues as infectious virus particles. Until now, no transmission of PERV has been observed in preclinical and clinical trials ([@CIT0010]). To prevent PERV transmission despite their integration in the pig genome, several strategies have been developed: 1) selection of pigs with a low copy number and a low expression of PERV-A and PERV-B proviruses; 2) selection of PERV-C free animals to avoid PERV-A/C recombinants with increased replication competence; 3) knockdown of PERV expression by RNA interference in transgenic pigs; and 4) vaccination against transmembrane and surface envelope proteins of PERV (reviewed in [@CIT0023]).

A breakthrough was achieved when the CRISPR/Cas9 technology was used to inactivate PERVs integrated in the pig genome. After proof of principle in immortalized PK-15 pig cells ([@CIT0055]), all PERV copies (altogether 25) were inactivated in primary pig cells and these were used for somatic cell nuclear transfer to produce live healthy piglets ([@CIT0040]). The technical feasibility of reducing the risk of PERV transmission to zero is exciting, but it is not clear at this stage if genome-wide PERV inactivation by CRISPR/Cas9 is actually required for entering clinical xenotransplantation trials.

Recent breakthrough in orthotopic pig-to-baboon cardiac xenotransplantation {#s6}
---------------------------------------------------------------------------

Heart transplantation is the only cure for patients with terminal cardiac failure, but the supply of human donor organs does not meet the clinical need. Xenotransplantation of genetically modified pig hearts is a potential alternative as demonstrated by long-term survival (up to 945 d) of genetically multimodified pig hearts (GGTA1 KO, hCD46/hTBM transgenic) after heterotopic abdominal transplantation in baboons ([@CIT0038]). Although this model demonstrated long-term acceptance of discordant cardiac xenotransplants with safe immunosuppression, their life supporting function remained to be proven. Therefore, [@CIT0031] used the same genetic background of donor pigs and adapted the immunosuppressive regimen developed by [@CIT0038] to perform a series of orthotopic heart transplantation (= heart replacement) experiments in baboons, finally resulting in consistent long-term success with survival times up to 195 d ([Figure 3](#F3){ref-type="fig"}). The most essential improvements were 1) specific perfusion preservation of the xeno-hearts after explantation and during implantation with 8 °C-oxygenated hyperoncotic cardioplegic solution containing nutrition, hormones, and erythrocytes; and 2) post-transplantation growth control of the xeno-hearts by early weaning of glucocorticoids, lowering the recipients' blood pressure, and inhibition of mTOR (mechanistic target of rapamycin) activation to counteract cardiomyocyte hypertrophy. Consistent life-supporting function of xeno-hearts for up to 195 d in the most relevant and stringent preclinical animal model is a milestone on the way to clinical cardiac xenotransplantation ([@CIT0031]).

![Factors enabling consistent success in life-supporting pig-to-baboon cardiac xenotransplantation. In addition to genetically multimodified porcine donor hearts (lacking αGal epitopes and expressing human CD46 as well as human thrombomodulin) and appropriate immunosuppression, two steps were key to success: 1) nonischemic preservation of the donor hearts by perfusion with oxygenated hyperoncotic blood-based solution; and 2) prevention of detrimental xeno-heart overgrowth by early weaning of cortisone, lowering of blood pressure and treatment with the mTOR inhibiting prodrug temsirolimus ([@CIT0031]).](vfz014f0003){#F3}

Conclusions and Perspectives {#s7}
============================

Recent studies of life-supporting cardiac ([@CIT0031]) and kidney xenotransplantation (survival \> 400 d; [@CIT0025]) in nonhuman primates have achieved survival times that the initiation of clinical xenotransplantation trials may be justified. This requires an internationally accepted regulatory framework covering safety and quality standards of donor pigs, requirements for preclinical data, selection and information of trial participants, post-transplant long-term patient follow-up, and storage of appropriate pre- and post-procedure specimens from donor pigs and patients. Pertinent recommendations from the Third WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials (Changsha, China, December 12--14, 2018) will be published as The 2018 Changsha Communiqué.
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